Abraxana is capable of halting progression of metastatic breast cancer

Abraxana has emerged as a more effective breast cancer treatment compared to Taxotere, researchers have discovered.

Findings by scientists at Northwestern University in the US showed that the less toxic, solvent-free chemotherapy drug is more capable of preventing the progression of metastatic breast cancer than the more commonly used solvent-based treatment.

It was also revealed that Abraxane has fewer side effects than its counterpart.

Study leader William Gradishar said the findings were "win-win".

"The weekly schedule of Abraxane has more anti-tumour effects and is better tolerated than Taxotere," he explained.

"There is also evidence that Abraxane is able to deliver the chemotherapy drug more effectively to the tumour."

Without containing chemical solvents, Abraxane uses albumin, a human protein, to deliver chemotherapy treatment.

Metastatic breast cancer involves the spread of a malignant tumour from the breast to other parts of the body.

A total of 45,000 women were diagnosed with breast cancer in the UK in 2006, making it the most common form of the disease in the country.

Comment on this page »


Latest news

AXA PPP healthcare win at UK Customer Experience awards 2015

David Mobbs retires as CEO of Nuffield Health

King's victorious at World Transplant Games

Abraxana is capable of halting progression of metastatic breast cancer
Connect with us on:

This site compiles with the HONcode standard for trustworthy health information